ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 787 USD | +3.19% |
|
+1.55% | +35.01% |
| 05-15 | Health Care Up on Momentum -- Health Care Roundup | DJ |
| 05-15 | UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down | RE |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.15% | 2,383 M€ | +13.64% | ||
| 1.11% | 34 M€ | +12.38% | - | |
| 1.09% | 375 M€ | +9.38% | ||
| 1.06% | 26 M€ | +20.69% | - | |
| 1.05% | 206 M€ | -.--% | ||
| 1.00% | 205 M€ | -.--% | ||
| 0.95% | 26 M€ | +16.85% | - | |
| 0.94% | 11 M€ | -6.03% | - | |
| 0.91% | 6 M€ | +17.98% | - | |
| 0.90% | 121 M€ | +8.33% | - | |
| 0.89% | 744 M€ | +8.72% | ||
| 0.89% | 8 M€ | +5.15% | - | |
| 0.87% | 1 M€ | +3.03% | - | |
| 0.84% | 224 M€ | +4.07% | - | |
| 0.84% | 26 M€ | +0.24% | - | |
| 0.84% | 24 M€ | +0.14% | - | |
| 0.83% | 50 M€ | +10.93% | ||
| 0.83% | 13 M€ | -.--% | - | |
| 0.83% | 4 M€ | -.--% | - | |
| 0.83% | 3 M€ | +15.16% | - | |
| 0.80% | 1,166 M€ | +0.26% | - | |
| 0.80% | 607 M€ | +0.05% | - | |
| 0.79% | 264 M€ | -.--% | - | |
| 0.79% | 187 M€ | +9.41% | - | |
| 0.79% | 477 M€ | +12.35% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.01% | 688B | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company